A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Phase of Trial: Phase II
Latest Information Update: 08 Oct 2018
At a glance
- Drugs ONC 201 (Primary)
- Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Male breast cancer
- Focus Therapeutic Use
- 28 Sep 2018 Planned number of patients changed from 94 to 90.
- 05 Apr 2018 According to the Oncoceutics media release, first patient has been treated in this trial.
- 17 Jan 2018 Status changed from not yet recruiting to recruiting.